Bicoll supports the development of a drug candidate for Huntington’s disease in collaboration with Galyan Bio
Clinical trials with novel small molecule to start in 2022
Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to identify new scaffold for first-in-class clinical candidates. The new treatments interfere in the protein quality control system and are subsequently also useful for healthy aging.
media@galyan.bio
Contacts /
For more information, please contact:
Rohit Shyam
Chief Business Officer